Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shweta Maurya has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Aseel Saadi

    The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, - 91120, Israel

    5 shared publications
  • Prince Kumar Singh

    The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel

    5 shared publications
  • Taige Zhang

    The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, - 91120, Israel

    4 shared publications
  • Tawfeeq Shekh-Ahmad

    The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel

    4 shared publications
  • Andreas Lieb

    Institute of Pharmacology, Medical University of Innsbruck, 6020, Innsbruck, Austria

    2 shared publications
  • Daphne Atlas

    The Alexander Silberman Institute of Life Science, The Hebrew University of Jerusalem, Jerusalem, Israel

    2 shared publications

Latest Publications

  • Open Access

    CDDO-EA Attenuates Acute Seizures and Suppresses Post-Status Epilepticus Epileptogenesis

    by Yara Sheeni, Prince Kumar Singh, Shweta Maurya, Sereen Sandouka, Tawfeeq Shekh-Ahmad

    We aimed to investigate the acute anticonvulsant and long-term antiepileptogenic effects of the synthetic triterpenoid CDDO-EA in complementary experimental models of epilepsy. CDDO-EA was evaluated in the pentylenetetrazol seizure model and a kainic acid-induced post-status epilepticus model. Acute seizure severity, latency to generalized seizures, oxidative stress and inflammatory markers, spontaneous recurrent seizures, and hippocampal neuronal survival were assessed. In the pentylenetetrazol model, CDDO-EA pretreatment reduced maximal seizure severity and prolonged the latency to stage V-VI seizures. These effects were associated with decreased inflammatory cytokine levels and malondialdehyde levels, alongside increased superoxide dismutase and catalase activities 24 h after pentylenetetrazol administration. In the post-status epilepticus model, two weeks of CDDO-EA treatment significantly delayed the onset of spontaneous recurrent seizures and produced sustained reductions in weekly seizure frequency and cumulative seizure burden. Histological analysis demonstrated greater neuronal preservation in the hippocampal CA1 and CA3 regions of CDDO-EA-treated animals compared with vehicle controls. CDDO-EA exerts both anticonvulsant and disease-modifying effects by attenuating seizure severity, restoring redox-inflammatory homeostasis, preserving hippocampal neurons, and suppressing epileptogenesis after status epilepticus, supporting its therapeutic potential as a novel strategy for epilepsy.


  • Top Cited Papers
    Open Access

    Thioredoxin-mimetic peptide attenuates epilepsy progression and neurocognitive deficits

    by Prince Kumar Singh, Shweta Maurya, Aseel Saadi, Sereen Sandouka, Taige Zhang, Orya Kadosh, Yara Sheeni, Valeria Martin, Daphne Atlas, Tawfeeq Shekh-Ahmad


  • Open Access

    Selective inhibition of NOX2 after status epilepticus attenuates epileptogenesis and cognitive impairment: A sex-dependent study

    by Prince Kumar Singh, Shweta Maurya, Aseel Saadi, Taige Zhang, Andreas Lieb, Tawfeeq Shekh-Ahmad


  • Open Access

    Sex-Dependent Modulation of Nox2-Mediated Oxidative Stress in Epilepsy

    by Prince Kumar Singh, Shweta Maurya, Aseel Saadi, Taige Zhang, Andreas Lieb, Tawfeeq Shekh-Ahmad

    NOX2-driven reactive oxygen species mediated oxidative stress and neuroinflammation play a critical role in the pathophysiology of neurological disorders such as epilepsy. However, sex-dependent differences in the regulation of NOX2 associated oxidative stress and neuroinflammation and therapeutic targeting remain largely unexplored. Although various NOX inhibitors have been investigated, many have poor specificity, toxicity, and lack sustained efficacy. There is an urgent need for selective NOX2 inhibitors capable of mitigating oxidative stress and driven neuroinflammation while accounting for their sex-dependent responses. In this study, we investigated the therapeutic potential of GSK2795039, a selective NOX2 inhibitor, in reducing seizure burden, oxidative stress-mediated neuronal damage, and cognitive impairment in a sex-specific manner. GSK2795039 target NOX2 and associated oxidative stress-driven neuroinflammation efficiently in male over female rats following status epilepticus. However, males exhibited a more pronounced therapeutic response, with greater reductions in seizure and interictal spiking frequency, and neuronal loss, as well as improved cognitive outcomes. The comparatively weaker response in females suggests a reliance on alternative antioxidant and neuroprotective pathways. Our findings underscore the importance of considering sex as a biological variable in epilepsy treatment and highlight GSK2795039 as a promising NOX2-targeted therapy with differential efficacy based on sex-dependent redox homeostasis and inflammatory regulation.

  • Open Access

    Thioredoxin-Mimetic Peptide (Cb3) Exhibits Antiepileptogenic Effects and Modifies Chronic Epilepsy in a Temporal Lobe Epilepsy Model

    by Prince Kumar Singh, Shweta Maurya, Aseel Saadi, Sereen Sandouka, Taige Zhang, Orya Kadosh, Yara Sheeni, Valeria Martin, Daphne Atlas, Tawfeeq Shekh-Ahmad

    Epilepsy is a chronic neurological disorder characterized by recurrent seizures, frequently driven by oxidative stress and neuroinflammation, which not only exacerbate disease progression but also contribute to pharmacoresistance. Despite the widespread use of anti-seizure medications, approximately 30–40% of patients remain refractory to treatment, underscoring the urgent need for novel therapeutic interventions that target underlying pathophysiological mechanisms. In this study, we investigated the thioredoxin-mimetic tripeptide TXM-CB3 (CB3), previously demonstrated to attenuate oxidative stress and neuroinflammatory cascades, as a disease-modifying agent for epilepsy. Initially, we evaluated the efficacy of CB3 in an in vitro epileptiform activity model to assess its capacity to suppress reactive oxygen species production and modulate inflammatory cytokine expression. Subsequently, we conducted two simultaneous preclinical trials to determine the anti-epileptogenic and anti-epileptic potential of CB3 while also assessing its neuroprotective effects against epilepsy-associated cognitive deficits and neuronal injury. Our findings reveal that CB3 significantly suppresses ROS generation and the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) while enhancing anti-inflammatory IL-10 expression during epileptiform activity in vitro. In vivo, CB3 markedly reduced seizure frequency, prolonged seizure latency, and mitigated cumulative seizure burden. Furthermore, CB3 conferred neuroprotection by preserving hippocampal neuronal integrity, attenuating oxidative-induced DNA/RNA damage, and ameliorating spatial memory deficits and anxiety-like behaviors. Notably, CB3 exhibited sustained therapeutic efficacy in the chronic phase of epilepsy without affecting locomotion or recognition memory. Collectively, our findings position CB3 as a potent disease-modifying therapeutic that disrupts the self-perpetuating cycle of oxidative stress and neuroinflammation, thereby reducing seizure burden and preserving neuronal function.


  • Natural Bioactive used for Alzheimer's and Other Dementias

    by Anshul Shakya, Bhargab Deka, Shuby Kumari, Sushil Kumar Chaudhary, Shweta Maurya, Amit Kumar, Hans Raj Bhat, Surajit Kumar Ghosh

    Natural bioactive compounds have become increasingly popular in research to explore their potential in the treatment of Alzheimer’s and other forms of dementia. Bioactive compounds are derived from natural sources, such as medicinal plants, and have been studied for their antioxidant, anti-inflammatory, and neuroprotective properties. Numerous studies have indicated that these compounds can play a role in reducing the progression of Alzheimer’s and other forms of dementia, as well as improving cognitive function. In particular, polyphenols have been studied for their ability to reduce oxidative damage and inflammation in the brain. Polyphenols are a diverse group of compounds that are found naturally in many fruits, vegetables, and herbs, and are known for their potent antioxidant properties. Studies have shown that polyphenols can inhibit the formation of amyloid plaques, which is a major hallmark of Alzheimer’s disease. Other natural bioactive compounds that have been studied for their potential to treat Alzheimer’s and other forms of dementia include omega-3 fatty acids, curcumin, and resveratrol. Omega-3 fatty acids have been shown to have anti-inflammatory and neuroprotective effects, while curcumin has been studied for its ability to reduce amyloid plaque formation and improve cognitive function. Resveratrol, a compound found in red wine, has also been studied for its potential to reduce inflammation and improve cognitive function. Overall, natural bioactive compounds have great potential to treat Alzheimer’s and other dementias. Using natural bioactive compounds is a promising area of research for treating Alzheimer’s and other forms of dementia. While further research is needed to confirm the efficacy of these compounds, the preliminary evidence suggests that they may offer a safe and effective way to reduce cognitive impairment and improve the quality of life for those affected by dementia.